JP2022525435A5 - - Google Patents
Info
- Publication number
- JP2022525435A5 JP2022525435A5 JP2021559648A JP2021559648A JP2022525435A5 JP 2022525435 A5 JP2022525435 A5 JP 2022525435A5 JP 2021559648 A JP2021559648 A JP 2021559648A JP 2021559648 A JP2021559648 A JP 2021559648A JP 2022525435 A5 JP2022525435 A5 JP 2022525435A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831123P | 2019-04-08 | 2019-04-08 | |
| US62/831,123 | 2019-04-08 | ||
| PCT/US2020/027071 WO2020210232A1 (en) | 2019-04-08 | 2020-04-07 | Cd19 antibodies and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525435A JP2022525435A (ja) | 2022-05-13 |
| JP2022525435A5 true JP2022525435A5 (https=) | 2023-04-13 |
| JP7730295B2 JP7730295B2 (ja) | 2025-08-27 |
Family
ID=72751761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559648A Active JP7730295B2 (ja) | 2019-04-08 | 2020-04-07 | Ｃｄ１９抗体およびこれを使用する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12612456B2 (https=) |
| EP (1) | EP3953385A4 (https=) |
| JP (1) | JP7730295B2 (https=) |
| KR (1) | KR20220006065A (https=) |
| CN (1) | CN114341176A (https=) |
| AU (1) | AU2020270888A1 (https=) |
| CA (1) | CA3136251A1 (https=) |
| IL (1) | IL287039A (https=) |
| WO (1) | WO2020210232A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| PL4269444T3 (pl) | 2020-08-14 | 2025-01-13 | GammaDelta Therapeutics Limited | Wieloswoiste przeciwciała anty-tcr zmienne delta 1 |
| CA3214628A1 (en) * | 2021-04-06 | 2022-10-13 | Memorial Sloan-Kettering Cancer Center | Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| AU2022412918A1 (en) * | 2021-12-15 | 2024-06-06 | Y-Mabs Therapeutics, Inc. | Formulations comprising a sada complex |
| CN119350497A (zh) * | 2023-07-24 | 2025-01-24 | 星尘生物科技(上海)有限公司 | 人源化抗cd19单链可变区片段及其用途 |
| WO2025077871A1 (zh) * | 2023-10-13 | 2025-04-17 | 苏州瑞博生物技术股份有限公司 | 缀合物、药物缀合物与组合物及制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102421800A (zh) * | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| GB201106357D0 (en) * | 2011-04-14 | 2011-06-01 | Pessi Antonello | Composition and uses thereof |
| CN104379169A (zh) * | 2012-08-14 | 2015-02-25 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| RU2016132863A (ru) * | 2014-01-15 | 2018-02-20 | Займворкс Инк. | БИСПЕЦИФИЧЕСКИЕ CD3 и CD19 АНТИГЕНСВЯЗЫВАЮЩИЕ КОНСТРУКЦИИ |
| US11820832B2 (en) * | 2014-07-25 | 2023-11-21 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| JP6871155B2 (ja) * | 2014-07-25 | 2021-05-12 | メモリアル スローン ケタリング キャンサー センター | 二重特異性ｈｅｒ２及びｃｄ３結合分子 |
| MX375669B (es) * | 2014-09-26 | 2025-03-06 | Macrogenics Inc | Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos. |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| EP3529268B1 (en) * | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| US11046768B2 (en) * | 2017-01-27 | 2021-06-29 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| AU2018257894A1 (en) * | 2017-04-24 | 2019-10-31 | Kite Pharma, Inc. | Humanized antigen-binding domains against CD19 and methods of use |
| EA201992546A1 (ru) * | 2017-04-24 | 2020-03-06 | Мемориал Слоан Кеттеринг Кэнсер Сентер | Средства на основе антител к cd33 |
| US11597764B2 (en) * | 2017-06-15 | 2023-03-07 | Memorial Sloan Kettering Cancer Center | Anti-L1-CAM antibodies and uses thereof |
| KR102820804B1 (ko) | 2017-09-22 | 2025-06-16 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체 |
| AU2018338322B2 (en) | 2017-09-23 | 2025-07-17 | Memorial Sloan Kettering Cancer Center | A33 antibody compositions and methods of using the same in radioimmunotherapy |
-
2020
- 2020-04-07 CA CA3136251A patent/CA3136251A1/en active Pending
- 2020-04-07 EP EP20788168.1A patent/EP3953385A4/en active Pending
- 2020-04-07 CN CN202080041527.2A patent/CN114341176A/zh active Pending
- 2020-04-07 JP JP2021559648A patent/JP7730295B2/ja active Active
- 2020-04-07 KR KR1020217036014A patent/KR20220006065A/ko active Pending
- 2020-04-07 US US17/602,176 patent/US12612456B2/en active Active
- 2020-04-07 AU AU2020270888A patent/AU2020270888A1/en active Pending
- 2020-04-07 WO PCT/US2020/027071 patent/WO2020210232A1/en not_active Ceased
-
2021
- 2021-10-06 IL IL287039A patent/IL287039A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022525435A5 (https=) | ||
| CN102174108B (zh) | 内在化抗-cd74抗体和使用方法 | |
| JP4733635B2 (ja) | 抗ｃｄ１９抗体 | |
| CA2529496C (en) | Anti-cd74 immunoconjugates and methods | |
| CA2599734C (en) | Humanized l243 antibodies | |
| JP2022546572A5 (https=) | ||
| JP2022538117A5 (https=) | ||
| JP7730295B2 (ja) | Ｃｄ１９抗体およびこれを使用する方法 | |
| JP2023523584A5 (https=) | ||
| JP2021517816A5 (https=) | ||
| IL273484B1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| KR20050027274A (ko) | 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법 | |
| JP2023537002A5 (https=) | ||
| JP2020523029A5 (https=) | ||
| US20250340637A1 (en) | Cd3 targeting antibodies and uses thereof | |
| JP2024530166A5 (https=) | ||
| CN101796073B (zh) | 针对cxcr3的人源化抗体 | |
| CN117279950B (zh) | 一种靶向il-18bp的抗体及其应用 | |
| CN111065409A (zh) | Strep-tag特异性结合蛋白及其用途 | |
| JP2025530159A (ja) | Ｃｃｒ８抗体の医学的使用および投与スケジュール | |
| CN117177999A (zh) | 一种靶向IL-18Rβ的抗体及其应用 | |
| JP2024514830A5 (https=) | ||
| CN119505001B (zh) | 靶向cd22的全人源抗体及其应用 | |
| JP2024531913A5 (https=) | ||
| WO2019197974A1 (en) | Anti-telomerase reverse transcriptase antibodies and use thereof |